Patents Assigned to BIOENERGENIX
  • Heterocyclic compounds for the inhibition of PASK
    Patent number: 11459307
    Abstract: Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.
    Type: Grant
    Filed: August 12, 2020
    Date of Patent: October 4, 2022
    Assignee: BioEnergenix LLC
    Inventors: John M. McCall, Donna L. Romero, John McKearn, Michael Clare
  • Heterocyclic compounds for the inhibition of PASK
    Patent number: 11191765
    Abstract: Disclosed herein are new heterocyclic compounds and compositions having structural Formula (I) and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: December 7, 2021
    Assignee: BioEnergenix LLC
    Inventors: John McCall, Robert C. Kelly, Donna L. Romero
  • Heterocyclic compounds for the inhibition of pask
    Patent number: 10953012
    Abstract: Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.
    Type: Grant
    Filed: April 26, 2012
    Date of Patent: March 23, 2021
    Assignee: BioEnergenix LLC
    Inventors: John M. McCall, Robert C. Kelly, Donna L. Romero
  • Heterocyclic compounds for the inhibition of PASK
    Patent number: 10781185
    Abstract: Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: September 22, 2020
    Assignee: BioEnergenix LLC
    Inventors: John M. McCall, Donna L. Romero, John McKearn, Michael Clare
  • Heterocyclic compounds for the inhibition of PASK
    Patent number: 10392389
    Abstract: Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.
    Type: Grant
    Filed: October 25, 2013
    Date of Patent: August 27, 2019
    Assignee: BioEnergenix LLC
    Inventors: John McCall, Robert C. Kelly, Donna L. Romero
  • Heterocyclic compounds for the inhibition of PASK
    Patent number: 9868708
    Abstract: Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.
    Type: Grant
    Filed: October 19, 2015
    Date of Patent: January 16, 2018
    Assignee: BioEnergenix LLC
    Inventors: John M. McCall, Donna L. Romero, John McKearn, Michael Clare
  • Substituted indoles for the inhibition of PASK
    Patent number: 9675584
    Abstract: Disclosed herein are substituted pyrazinyl acrylic acids of Formula (II): and compositions thereof, which may be useful as inhibitors of PAS Kinase (PASK) activity in a human or animal for the treatment of diseases such as diabetes mellitus.
    Type: Grant
    Filed: March 19, 2015
    Date of Patent: June 13, 2017
    Assignee: BioEnergenix, LLC
    Inventors: John M. McCall, Donna L. Romero, Michael Clare
  • PAS kinase assays
    Patent number: 9476881
    Abstract: The present invention is directed towards methods for measuring and assaying PAS Kinase activity. The methods are useful, for example, for detecting PASK activity in a cell, and for screening for small molecule regulators of PAS kinase activity, as well as characterizing endogenous factors and stimuli that modulate PAS kinase activity, and identifying and optimizing the activity of potential PAS kinase inhibitors.
    Type: Grant
    Filed: September 12, 2014
    Date of Patent: October 25, 2016
    Assignee: BioEnergenix LLC
    Inventors: Jared Paul Rutter, Wojciech Ireneusz Swiatek
  • Heterocyclic compounds for the inhibition of PASK
    Patent number: 9370522
    Abstract: Disclosed herein are new heterocyclic compounds having structural Formula IIa and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: June 21, 2016
    Assignee: BioEnergenix, LLC
    Inventors: John M. McCall, Donna L. Romero, Michael Clare
  • Heterocyclic compounds for the inhibition of PASK
    Patent number: 9278973
    Abstract: Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.
    Type: Grant
    Filed: October 25, 2013
    Date of Patent: March 8, 2016
    Assignee: BIOENERGENIX LLC
    Inventors: John McCall, Robert C. Kelly, Donna L. Romero
  • Heterocyclic compounds for the inhibition of PASK
    Patent number: 9193693
    Abstract: Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.
    Type: Grant
    Filed: September 29, 2014
    Date of Patent: November 24, 2015
    Assignee: BioEnergenix LLC
    Inventors: John M. McCall, Donna L. Romero, John McKearn, Michael Clare
  • Substituted quinoxaline carboxylic acid compounds for the inhibition of PASK
    Patent number: 9073902
    Abstract: Disclosed herein are substituted quinoxaline carboxylic acids of Formula (I): and compositions thereof, which may be useful as inhibitors of PAS Kinase (PASK) activity in a human or animal for the treatment of diseases such as diabetes mellitus.
    Type: Grant
    Filed: January 5, 2012
    Date of Patent: July 7, 2015
    Assignee: BioEnergenix, LLC
    Inventors: John M. McCall, Donna L. Romero
  • Substituted pyrazinyl acrylic acid compounds for the inhibition of pask
    Patent number: 9012637
    Abstract: Disclosed herein are substituted pyrazinyl acrylic acids of Formula (IV): and compositions thereof, which may be useful as inhibitors of PAS Kinase (PASK) activity in a human or animal for the treatment of diseases such as diabetes mellitus.
    Type: Grant
    Filed: April 28, 2014
    Date of Patent: April 21, 2015
    Assignee: BioEnergenix, LLC
    Inventors: John M. McCall, Donna L. Romero, Michael Clare
  • Substituted quinoxaline compounds for the inhibition of PASK
    Patent number: 8916561
    Abstract: Disclosed herein are substituted quinoxaline of Formula (I): and compositions thereof, which may be useful as inhibitors of PAS Kinase (PASK) activity in a human or animal for the treatment of diseases such as diabetes mellitus.
    Type: Grant
    Filed: March 2, 2012
    Date of Patent: December 23, 2014
    Assignee: BioEnergenix, LLC
    Inventors: John M. McCall, Donna L. Romero
  • Heterocyclic compounds for the inhibition of PASK
    Patent number: 8916560
    Abstract: Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.
    Type: Grant
    Filed: February 29, 2012
    Date of Patent: December 23, 2014
    Assignee: BioEnergenix, LLC
    Inventors: John M. McCall, John McKearn, Donna L. Romero, Michael Clare
  • Substituted quinoxaline carboxylic acids for the inhibition of PASK
    Patent number: 8912188
    Abstract: Disclosed herein are substituted quinoxaline carboxylic acids of Formula (I): and compositions thereof, which may be useful as inhibitors of PAS Kinase (PASK) activity in a human or animal for the treatment of diseases such as diabetes mellitus.
    Type: Grant
    Filed: March 2, 2012
    Date of Patent: December 16, 2014
    Assignee: BioEnergenix, LLC
    Inventors: John M. McCall, Donna L. Romero, Robert C. Kelly
  • HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK
    Publication number: 20140128392
    Abstract: Disclosed herein are new heterocyclic compounds of Formula IIa: and compositions thereof, and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.
    Type: Application
    Filed: March 19, 2010
    Publication date: May 8, 2014
    Applicant: BIOENERGENIX
    Inventors: John M. McCall, Donna L. Romero
  • HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK
    Publication number: 20120277224
    Abstract: Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.
    Type: Application
    Filed: April 26, 2012
    Publication date: November 1, 2012
    Applicant: BIOENERGENIX
    Inventors: John M. McCall, Robert C. Kelly, Donna L. Romero
  • HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK
    Publication number: 20120232056
    Abstract: Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.
    Type: Application
    Filed: March 2, 2012
    Publication date: September 13, 2012
    Applicant: BIOENERGENIX
    Inventors: John M. McCall, Donna L. Romero, Robert C. Kelly
  • HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK
    Publication number: 20120225863
    Abstract: Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.
    Type: Application
    Filed: March 2, 2012
    Publication date: September 6, 2012
    Applicant: BIOENERGENIX
    Inventors: John M. McCall, Donna L. Romero